 |
|
Klebsiella pneumoniae carbapenemase
Some of the class, as well, an enzyme known for plasmid-mediated KPC enzyme best is carbapenemase effective. 10 variants with KPC-11, KPC-2 is (that is sequenced in 2008 again to CPC-1, which is 100% homologous to the published sequence of the CPC-2) amino acid substitution of one or two thereof is characterized by, and are well known. CPC-1 was found North Carolina, in the KPC-2 in the KPC-3 Baltimore and New York. NMC / IMI enzymes and SME has an identity of 45%, they can, in contrast, independently, to encode the transmission plasmid. Currently, since it was found in North Carolina first in 1996, class Klebsiella pneumoniae carbapenemase is carbapenemase, the most common is spreading all over the world (KPC). The publication, the intestinal bacteria that produce the CPC, that it has become common in the United States has been shown later.
Clinical Significance
Can cause disease K. pneumonia, pneumonia, Klebsiella. They cause a change destructive lung of people with cell death generated bleeding (necrosis) and (Sugurizeri sputum) inflammation, thick mucus and sometimes bloody sputum. After aspiration the pharyngeal microorganisms colonize the lower respiratory tract, these bacteria, he to gain access Standard. As a general rule, Klebsiella infections occur mainly in people with immune systems weakened. The most common diseases that affect men Mature debilitating disease. This population, including people with and workers in paper mill (eg occupational exposure of specific diabetes, alcoholism, malignant disease, liver disease, chronic obstructive pulmonary disease (COPD), glucocorticoid therapy, and renal failure, It is considered to have, a failure respiratory protection host). When you are hospitalized for (nosocomial infection) for other reasons, many of these infections will occur people. Most common infectious diseases caused by Klebsiella pneumoniae outer Hospital bacteria in the form of bronchitis and pneumonia in general. Tend to develop lung abscess increased, these patients have a Ural adhesion cavitation, and empyema. It also has an antimicrobial therapy, the mortality rate high about 50%. Mortality can be almost 100% of people with bacteremia and alcoholism. It is possible that in addition to pneumonia, Klebsiella also cause the infection of surgical site urinary tract, biliary tract under, and scratches. People of sepsis inch pneumonia, thrombophlebitis, urinary tract infection (UTI), cholecystitis, diarrhea, upper respiratory tract infection, wound, osteomyelitis, meningitis, and bacteremia is invasive of your body the pollution in the range of device clinical disease, including the later will be the risk breathing assistance put patients at risk like that, such as urinary catheters if you have a device basis. The use of antibiotics, may be a factor that increases the risk of nosocomial infections caused by Klebsiella bacteria. Sepsis and septic shock, you can follow the invasion of bacteria into the blood.
Resistant strains
Infection of carbapenemase carbapenem-resistant intestinal bacteria that produce intestinal bacteria or (CRE), is emerging as an important issue in health care facilities. Carbapenem-resistant Klebsiella pneumoniae one carbapenem-resistant intestinal bacteria of many (CRE) is (CRKP). There CRKP increased gradually over the past 10 years, has seen the world, but fashion is best known in Israel that began around 2006 in the health care system there, this emerging nosocomial pathogen, is probably. The United States, has been described in North Carolina in 1996 first; CRKP because it is restored in some hospitals in New Jersey and New York daily and identified in 41 countries. Currently, this is most common species found in the CRE in the United States. Among those who have received (for example, central venous catheter and fan) invasive device and critically ill and those hospitalized in particular, cause CRKP morbidity and mortality is high, CRKP infection and available antibacterial agents of almost all is resistant to. Concern is that carbapenem that has been used as a drug of last frequently when fighting resistant strains. Concern is very low, but if anything, it is that you can be new passenger mutations lead to infection because it is there, health professionals, can be done to treat resistant bacteria patient. There are several mechanisms of carbapenem resistance in enteric bacteria. They outflow of drug or a broad spectrum of β-lactamase porin mutations, and are included with the AmpC type outer membrane porin mutations (3) carbapenemase β-lactamase (2) CTX-M (1) is overproduction . When you produce an enzyme known as carbapenemase bacteria such as Klebsiella pneumonia like this, there is more resistant to (CRKP) carbapenem Klebsiella pneumonia them. In other words, the most important mechanism in the resistance of CRKP is a carbapenemase enzyme production, the blakpc. Gene encoding the enzyme is carried out with respect to the movable portion (the specific involvement transposon called transposons, and Tn4401) genetic material that increases the risk of seeding blakpc. have, minimum inhibitory concentrations Some strains that harbor blakpc has risen (MIC), but since it is in the range of carbapenem still susceptible, detecting CRE may be difficult . These strains are susceptible to carbapenems, have been identified as risk of infection or clinical potential to control with the standard guidelines for susceptibility testing. Patients with CRKP colony that has not been recognized is a reservoir for transmission of nosocomial outbreak at the time.
GENTAUR Belgium BVBA BE0473327336 Voortstraat 49, 1910 Kampenhout BELGIUM Tel 0032 16 58 90 45 Fax 0032 16 50 90 45 [email protected] GENTAUR Ltd. GB111298832 Howard Frank Turnberry House 1404-1410 High Road Whetstone London N20 9BH Tel 020 3393 8531 Fax 020 8445 9411 |
GENTAUR France SARL FR63484237888 9, rue Lagrange, 75005 Paris Tel 01 43 25 01 50 Fax 01 43 25 01 60 RCS Paris B 484 237 888 SIRET 48423788800017 RIB 30004 00187 00010092253 10 BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG IBAN FR76 3000 4001 8700 0100 9225 310 [email protected] |
GENTAUR GmbH DE815175831 Marienbongard 20 52062 Aachen Deutschland [email protected] Tel 0241 95 78 94 78 Tacka Vancheva Tel logistics 0241 4008 9086 Annick Verdeyen Fax 0241 55 91 05 36 Bankleitzahl 39050000 IBAN DE8839050000107569353 Handelsregister Aachen HRB16058 Steuernummer 201/5961/3925 [email protected] |
GENTAUR Nederland BV NL850396268B01 Kuiper 1 5521 DG Eersel Nederland KVK nummer 52327027 Tel: 0208-080893 Fax: 0497-517897 [email protected] IBAN: NL04RABO0156985462 SWIFT RABONL2U GENTAUR Ltd. GB111298832 Howard Frank Turnberry House 1404-1410 High Road Whetstone London N20 9BH Tel 020 3393 8531 Fax 020 8445 9411 |
GENTAUR U.S.A Genprice Inc, Logistics 547, Yurok Circle San Jose, CA 95123 Phone: (408) 472-2934 Fax:(408) 416-3994 Phone (718)513-2983 [email protected] Genprice Inc, Invoices and accounting 6017 Snell Ave San Jose, CA 95123 |
GENTAUR Italy 20135 Milano Tel 0236006593 Fax 0350085071 [email protected] GENTAUR Spain tel:0911876558 [email protected] GENTAUR BULGARIA BG20135893153, Graf Ignatiev Str. ent.V, fl. 2 Sofia 1000 Tel 0035929830070 Fax 0035929830072 [email protected] |
ГЕНТАУЪР БЪЛГАРИЯ ID # 201 358 931 BULSTAT София 1000 ул. "Граф Игнатиев" 53 вх. В, ет. 2 Tel 0035929830070 Fax 0035929830072 e-mail: [email protected] IBAN: BG11FINV91501014771636 BIC: FINVBGSF |
Other countries Österreich +43720880899 Canada Montreal +15149077481 Ceská republika Praha +420246019719 Danmark +4569918806 Finland Helsset +358942419041 Magyarország Budapest +3619980547 Ireland Dublin +35316526556 Luxembourg +35220880274 Norge Oslo +4721031366 Sverige Stockholm +46852503438 Schweiz Züri +41435006251 US New York +17185132983 |